Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Incyte, Hengrui In 'Biggest Ever' China Pharma Out-Licensing Deal

This article was originally published in Scrip

Executive Summary

In an alliance that illustrates the growing attractiveness of rising innovative R&D capabilities at selected Chinese pharma firms, the US oncology-focused company Incyte Corp. has acquired development and commercialization rights in most global markets to SHR-1210, a PD-1-targeting antibody developed by Jiangsu Hengrui Medicine Co. Ltd.


Related Content

Fosun Pharma, Shanghai Pharma Deny Interest In Stada
Hengrui Pursues Innovation Through New $100m US Spinoff
Immuno-Oncology's Next Wave: Key Targets And Emerging Players


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts